about
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.Advances in understanding pituitary tumorsInvasive adenoma and pituitary carcinoma: a SEER database analysisTemozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factorO-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysisThree-dimensional reconstruction and morphological characterization of pituitary macroadenomas.Whole-exome sequencing identifies variants in invasive pituitary adenomas.Refractory pituitary adenoma: a novel classification for pituitary tumors.Investigational therapies for acromegaly.Aggressive tumors and difficult choices in acromegaly.Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.Aggressive pituitary adenomas--diagnosis and emerging treatments.Progress in the Diagnosis and Classification of Pituitary Adenomas.The safety of treatments for prolactinomas.Management of aggressive growth hormone secreting pituitary adenomas.Silencing of the Smad nuclear interacting protein 1 (SNIP1) by siRNA inhibits proliferation and induces apoptosis in pituitary adenoma cells.Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.Cytohistological correlation in pituitary tumor and immunological assessment with the help of Ki-67Germline Mutations in CDH23, Encoding Cadherin-Related 23, Are Associated with Both Familial and Sporadic Pituitary Adenomas.Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas.HMGA2 cooperates with either p27(kip1) deficiency or Cdk4(R24C) mutation in pituitary tumorigenesis.Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
P2860
Q30987978-81E40AF9-493F-4350-89E0-E7D18F1A27E5Q34660143-30F4471E-42A9-497D-8D34-87B1F48CBCA5Q35067759-9E95A7B3-0F8D-4197-9D00-AFB1555116C8Q35708559-74ED9227-164D-4821-8034-FD98ED1F6512Q35935026-16B96155-C66C-41A4-8A02-660CFB1565C9Q36268061-D3E2918B-5227-4109-96C7-0FDD8005A0F1Q36958299-D6235ABE-9F41-481C-AAA7-99CD6EC7F7D9Q37288391-252CDCF7-56FF-4FA1-B0B9-AD726578229CQ37696359-34DB14CF-50C0-4751-BFE7-7EC4429FC4C3Q38111437-F1210D0C-610B-405E-9D43-C23E6B85352CQ38167711-D4287494-B687-4B3B-9B95-9C85D972DDF4Q38169995-B535E159-B99B-4A7E-8BE4-E707C929D5FFQ38211375-46B4C3A7-542B-45A7-A40F-94B744C7B630Q38540507-2647577A-9BD1-4C6F-8ED4-98BCEF6BFA66Q38726058-F9E3DFBB-D880-4219-A232-BD51B5866DAEQ38781620-2B688053-18BF-4556-9193-513C15F51AF6Q39118403-C771D2FD-F3D5-4F2C-8201-AC8D007459FEQ39169799-D6EB9044-87F7-4FD5-96A5-1549782D8864Q42289816-FF4D34C6-AF6B-4F53-A91C-16629D3C3731Q43086692-0C0BEFCA-FC91-493B-8CB7-E8934C632C2AQ44682096-EA9B59AF-C7F9-4AF2-8CE4-9A6CA1E2143FQ47382950-F5E8FD95-3AAB-448E-AC8F-75BD9783C754Q53629828-52E91589-2990-4D6D-8467-D9126CBE2E62
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapy of aggressive pituitary tumors.
@en
Therapy of aggressive pituitary tumors.
@nl
type
label
Therapy of aggressive pituitary tumors.
@en
Therapy of aggressive pituitary tumors.
@nl
prefLabel
Therapy of aggressive pituitary tumors.
@en
Therapy of aggressive pituitary tumors.
@nl
P2860
P50
P1476
Therapy of aggressive pituitary tumors.
@en
P2093
Ludovica F S Grasso
P2860
P304
P356
10.1517/14656566.2011.568478
P407
P577
2011-03-24T00:00:00Z